John O Miners

List of Publications by Year in Descending Order

244 papers	14,171 citations	66 h-index	108 g-index
253 ext. papers	15,102 ext. citations	4.5 avg, IF	6.37 L-index

#	Paper	IF	Citations
244	Inhibitory effects of non-steroidal anti-inflammatory drugs on human liver microsomal morphine glucuronidation: Implications for drug-drug interaction liability.. *Drug Metabolism and Pharmacokinetics*, **2021**, 42, 100442	2.2	1
243	Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. *Pharmacology & Therapeutics*, **2021**, 218, 107689	13.9	10
242	Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs). *Methods in Molecular Biology*, **2021**, 2342, 301-338	1.4	1
241	Binding of SEP-363856 within TAAR1 and the 5HT receptor: implications for the design of novel antipsychotic drugs. *Molecular Psychiatry*, **2021**,	15.1	3
240	Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 19, 1037-1044	7.3	2
239	Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes. *Journal of Hypertension*, **2021**, 39, 1274-1281	1.9	2
238	Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure. *AAPS Journal*, **2021**, 23, 15	3.7	3
237	Binding of clozapine to the GABA receptor: clinical and structural insights. *Molecular Psychiatry*, **2020**, 25, 1910-1919	15.1	24
236	Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 374, 438-451	4.7	7
235	Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 1191-1199	7.3	8
234	Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. *JAMA Oncology*, **2020**, 6, 512-518	13.4	85
233	Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma. *Cancer Chemotherapy and Pharmacology*, **2020**, 85, 615-620	3.5	6
232	Arginine-259 of UGT2B7 Confers UDP-Sugar Selectivity. *Molecular Pharmacology*, **2020**, 98, 710-718	4.3	2
231	Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202. *Biochemical Pharmacology*, **2019**, 169, 113616	6	16
230	Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity. *European Journal of Clinical Pharmacology*, **2019**, 75, 1211-1218	2.8	2
229	Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. *Drug Metabolism and Disposition*, **2019**, 47, 616-631	4	5
228	Drug and Chemical Glucosidation by Control Supersomes and Membranes from (Sf) 9 Cells: Implications for the Apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5. *Drug Metabolism and Disposition*, **2019**, 47, 271-278	4	1

227	Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin. *British Journal of Clinical Pharmacology*, **2018**, 84, 392-393	3.8	1
226	Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. *Biochemical Pharmacology*, **2017**, 129, 85-95	6	51
225	The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 436-449	6.1	41
224	Advances in drug metabolism and pharmacogenetics research in Australia. *Pharmacological Research*, **2017**, 116, 7-19	10.2	8
223	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. *Journal of Personalized Medicine*, **2017**, 8,	3.6	86
222	A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. *BMJ Open*, **2017**, 7, e018100	3	16
221	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 31-49	5.5	37
220	In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes. *Xenobiotica*, **2017**, 47, 461-469	2	1
219	A Fragment-Based Approach for the Computational Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes. *Drug Metabolism and Disposition*, **2016**, 44, 1794-1798	4	7
218	A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1033-1034, 17-26	3.2	9
217	In Vitro Drug Metabolism Using Liver Microsomes. *Current Protocols in Pharmacology*, **2016**, 74, 7.8.1-7.8.24	4	37
216	Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy. *Pharmacogenetics and Genomics*, **2016**, 26, 453-61	1.9	3
215	Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition. *Drug Metabolism and Disposition*, **2016**, 44, 378-88	4	21
214	Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling. *Pharmacogenetics and Genomics*, **2016**, 26, 44-50	1.9	9
213	Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. *British Journal of Clinical Pharmacology*, **2016**, 81, 1153-64	3.8	39
212	Cytochrome P450 structure-function: insights from molecular dynamics simulations. *Drug Metabolism Reviews*, **2016**, 48, 434-52	7	51
211	Haemodynamic effects of parenteral vs. enteral paracetamol in critically ill patients: a randomised controlled trial. *Anaesthesia*, **2016**, 71, 1153-62	6.6	12
210	Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins. *Xenobiotica*, **2015**, 45, 847-57	2	5

209	Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions. *Drug Metabolism and Disposition*, **2015**, 43, 1468-76	4	30
208	In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism. *Drug Metabolism and Disposition*, **2015**, 43, 1806-14	4	31
207	The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes. *Drug Metabolism and Disposition*, **2015**, 43, 1934-7	4	21
206	Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition. *Drug Metabolism and Disposition*, **2015**, 43, 147-53	4	14
205	Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modeling perspective. *Drug Metabolism Reviews*, **2015**, 47, 335-45	7	17
204	Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. *European Journal of Clinical Pharmacology*, **2014**, 70, 1097-106	2.8	52
203	Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. *European Journal of Clinical Pharmacology*, **2014**, 70, 1115-22	2.8	16
202	Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 349, 126-37	4.7	45
201	Molecular dynamics simulations: from structure function relationships to drug discovery. *In Silico Pharmacology*, **2014**, 2, 4	4.3	45
200	Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs). *Methods in Molecular Biology*, **2014**, 1113, 203-28	1.4	9
199	The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. *International Journal of Biochemistry and Cell Biology*, **2013**, 45, 1121-32	5.6	422
198	Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). *British Journal of Clinical Pharmacology*, **2013**, 76, 587-602	3.8	118
197	The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. *Drug Metabolism and Disposition*, **2013**, 41, 1273-84	4	36
196	Mass or molar? Recommendations for reporting concentrations of therapeutic drugs. *Medical Journal of Australia*, **2013**, 198, 368-9	4	5
195	Generation, validation, and application of a P450 homology model. *Current Topics in Medicinal Chemistry*, **2013**, 13, 2233-40	3	2
194	The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. *Pharmacology & Therapeutics*, **2012**, 134, 200-18	13.9	75
193	Amino Acid Conjugation: A Novel Route of Xenobiotic Carboxylic Acid Metabolism in Man **2012**, 1		2
192	Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. *Biochemical Pharmacology*, **2012**, 84, 1511-21	6	20

191	Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymes. *Journal of Biological Chemistry*, **2012**, 287, 24122-30	5.4	23
190	Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance. *Drug Metabolism and Disposition*, **2012**, 40, 982-9	4	34
189	Differential disposition of intra-renal generated and preformed glucuronides: studies with 4-methylumbelliferone and 4-methylumbelliferyl glucuronide in the filtering and nonfiltering isolated perfused rat kidney. *Journal of Pharmacy and Pharmacology*, **2011**, 63, 507-14	4.8	7
188	What's in a name?. *British Journal of Clinical Pharmacology*, **2011**, 71, 785-6; author reply 787-90	3.8	1
187	Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. *British Journal of Clinical Pharmacology*, **2011**, 71, 727-36	3.8	53
186	Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling. *Biochemical Pharmacology*, **2011**, 82, 2016-23	6	23
185	In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. *European Journal of Clinical Pharmacology*, **2011**, 67, 815-24	2.8	38
184	Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. *Drug Metabolism and Disposition*, **2011**, 39, 1324-8	4	28
183	Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. *Therapeutic Advances in Drug Safety*, **2011**, 2, 253-61	3.5	11
182	Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. *Drug Metabolism and Disposition*, **2011**, 39, 644-52	4	93
181	Application of homology modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine. *Molecular Pharmacology*, **2011**, 80, 879-88	4.3	13
180	Application of the fluorescent probe 1-anilinonaphthalene-8-sulfonate to the measurement of the nonspecific binding of drugs to human liver microsomes. *Drug Metabolism and Disposition*, **2011**, 39, 1711-7	4	6
179	The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. *Molecular Pharmacology*, **2011**, 79, 472-8	4.3	56
178	Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. *Drug Metabolism and Disposition*, **2010**, 38, 1011-4	4	8
177	Inhibition of morphine metabolism by ketamine. *Drug Metabolism and Disposition*, **2010**, 38, 728-31	4	21
176	In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 334, 609-18	4.7	68
175	Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. *Drug Metabolism Reviews*, **2010**, 42, 63-73	7	36
174	Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. *Expert Review of Clinical Pharmacology*, **2010**, 3, 769-76	3.8	55

173	The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. *Drug Metabolism Reviews*, **2010**, 42, 196-208	7	186
172	Nanoscale structure of lipid domain boundaries. *Soft Matter*, **2010**, 6, 2193	3.6	10
171	The In Vitro Characterization of Inhibitory Drug–Drug Interactions Involving UDP-Glucuronosyltransferase **2010**, 217-236		8
170	In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. *European Journal of Clinical Pharmacology*, **2010**, 66, 275-83	2.8	14
169	Response to Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as differentiating factor. *European Journal of Clinical Pharmacology*, **2010**, 66, 957-958	2.8	4
168	AFM study of the interaction of cytochrome P450 2C9 with phospholipid bilayers. *Chemistry and Physics of Lipids*, **2010**, 163, 182-9	3.7	15
167	Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. *Drug Metabolism and Disposition*, **2009**, 37, 1395-403	4	30
166	Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. *Drug Metabolism and Disposition*, **2009**, 37, 1948-55	4	48
165	Assessment of inter-individual variability in predicted phenytoin clearance. *European Journal of Clinical Pharmacology*, **2009**, 65, 1203-10	2.8	13
164	Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. *British Journal of Clinical Pharmacology*, **2009**, 68, 402-12	3.8	44
163	Kinetics membrane disruption due to drug interactions of chlorpromazine hydrochloride. *Langmuir*, **2009**, 25, 1086-90	4	16
162	Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. *British Journal of Clinical Pharmacology*, **2008**, 65, 87-97	3.8	32
161	Macrolide-theophylline interactions: no role for the inhibition of cytochrome P4501A2. *British Journal of Clinical Pharmacology*, **2008**, 66, 898-900	3.8	5
160	In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. *Biochemical Pharmacology*, **2008**, 76, 249-57	6	42
159	Lateral heterogeneities in supported bilayers from pure and mixed phosphatidylethanolamine demonstrating hydrogen bonding capacity. *Biointerphases*, **2008**, 3, 96-104	1.8	20
158	Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates. *Journal of Medicinal Chemistry*, **2008**, 51, 780-91	8.3	67
157	Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. *Journal of Biological Chemistry*, **2008**, 283, 36205-10	5.4	67
156	The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. *Drug Metabolism and Disposition*, **2008**, 36, 870-7	4	66

155	Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. *Molecular Pharmacology*, **2008**, 74, 1152-62	4.3	50
154	Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates. *Current Drug Metabolism*, **2008**, 9, 60-9	3.5	19
153	The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. *Drug Metabolism and Disposition*, **2008**, 36, 2307-15	4	94
152	The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. *Drug Metabolism and Disposition*, **2008**, 36, 1056-62	4	133
151	Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. *Expert Opinion on Drug Metabolism and Toxicology*, **2007**, 3, 159-68	5.5	69
150	Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. *Chemical Research in Toxicology*, **2007**, 20, 1520-7	4	15
149	In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. *Expert Opinion on Drug Metabolism and Toxicology*, **2007**, 3, 321-9	5.5	52
148	Characterisation of the binding of cationic amphiphilic drugs to phospholipid bilayers using surface plasmon resonance. *ChemMedChem*, **2007**, 2, 366-73	3.7	22
147	Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes. *British Journal of Clinical Pharmacology*, **2007**, 63, 380-1; author reply 381-2	3.8	3
146	Authors' reply: Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: emotional stress could be the explanation. *British Journal of Clinical Pharmacology*, **2007**, 63, 502-502	3.8	0
145	Quality of requests for serum digoxin concentrations: experience from an Australian regional health service. *British Journal of Clinical Pharmacology*, **2007**, 63, 623-7	3.8	6
144	Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. *British Journal of Clinical Pharmacology*, **2007**, 64, 450-7	3.8	43
143	Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. *Biochemical Pharmacology*, **2007**, 73, 1463-73	6	41
142	Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. *Biochemical Pharmacology*, **2007**, 73, 1683-91	6	46
141	Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 321, 137-47	4.7	132
140	The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. *Drug Metabolism and Disposition*, **2007**, 35, 363-70	4	45
139	Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. *Molecular Pharmacology*, **2007**, 72, 1054-62	4.3	48
138	Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 323, 422-30	4.7	32

137	Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. *Pharmacogenetics and Genomics*, **2007**, 17, 1017-29	1.9	76
136	Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis. *Archives of Biochemistry and Biophysics*, **2007**, 468, 58-69	4.1	27
135	Dynamics of Phospholipid Membrane Growth and Drug-Membrane Interactions Probed by Atomic Force Microscopy. *Journal of Scanning Probe Microscopy*, **2007**, 2, 41-45		6
134	Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. *European Journal of Clinical Pharmacology*, **2006**, 62, 203-8	2.8	66
133	In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. *Biochemical Pharmacology*, **2006**, 71, 1531-9	6	192
132	Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9. *Drug Metabolism and Disposition*, **2006**, 34, 1950-3	4	26
131	In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. *Drug Metabolism and Disposition*, **2006**, 34, 1055-62	4	173
130	Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. *Drug Metabolism and Disposition*, **2006**, 34, 449-56	4	203
129	Measurement of human cytochrome P4501A2 (CYP1A2) activity in vitro. *Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]*, **2006**, Chapter 4, Unit4.19	1	4
128	Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. *Journal of Chemical Information and Modeling*, **2006**, 46, 2661-73	6.1	31
127	Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. *Pharmacogenetics and Genomics*, **2006**, 16, 321-9	1.9	43
126	Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. *British Journal of Clinical Pharmacology*, **2006**, 61, 427-39	3.8	138
125	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. *British Journal of Clinical Pharmacology*, **2006**, 61, 570-84	3.8	58
124	Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?. *British Journal of Clinical Pharmacology*, **2006**, 61, 738-40	3.8	29
123	The importance of local chemical structure for chemical metabolism by human uridine 5'-diphosphate-glucuronosyltransferase. *Journal of Chemical Information and Modeling*, **2006**, 46, 2692-7	6.1	31
122	Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity. *Expert Opinion on Drug Metabolism and Toxicology*, **2005**, 1, 399-408	5.5	20
121	"Phase I and Phase II" drug metabolism: terminology that we should phase out?. *Drug Metabolism Reviews*, **2005**, 37, 575-80	7	67
120	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. *British Journal of Clinical Pharmacology*, **2005**, 60, 423-33	3.8	87

119	Electrochemical characterisation of the human cytochrome P450 CYP2C9. *Biochemical Pharmacology*, **2005**, 69, 1533-41	6	65
118	Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. *Pharmacogenetics and Genomics*, **2005**, 15, 677-85	1.9	640
117	Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. *Drug Metabolism and Disposition*, **2004**, 32, 413-23	4	296
116	Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. *Xenobiotica*, **2004**, 34, 49-60	2	22
115	Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. *Molecular Pharmacology*, **2004**, 65, 301-8	4.3	59
114	Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 311, 996-1007	4.7	76
113	Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. *Biochemical Pharmacology*, **2004**, 67, 191-9	6	75
112	Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. *Journal of Molecular Graphics and Modelling*, **2004**, 22, 507-17	2.8	47
111	Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. *Biochemistry*, **2004**, 43, 7834-42	3.2	24
110	Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. *Annual Review of Pharmacology and Toxicology*, **2004**, 44, 1-25	17.9	189
109	Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. *Journal of Medicinal Chemistry*, **2004**, 47, 5311-7	8.3	42
108	Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. *Journal of Medicinal Chemistry*, **2003**, 46, 1617-26	8.3	64
107	Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. *Drug Metabolism and Disposition*, **2003**, 31, 1086-9	4	175
106	Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. *Journal of Chemical Information and Computer Sciences*, **2003**, 43, 2019-24		67
105	In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity. *Clinical and Experimental Pharmacology and Physiology*, **2003**, 30, 836-40	3	18
104	Polymorphic hydroxylation of perhexiline in vitro. *British Journal of Clinical Pharmacology*, **2003**, 55, 635-8	3.8	25
103	In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. *British Journal of Clinical Pharmacology*, **2002**, 54, 493-503	3.8	99
102	Evolution of drug metabolism: hitchhiking the technology bandwagon. *Clinical and Experimental Pharmacology and Physiology*, **2002**, 29, 1040-4	3	15

101	Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. *Toxicology*, **2002**, 181-182, 453-6	4.4	150
100	CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response. *Pharmacogenetics and Genomics*, **2002**, 12, 91-2		16
99	Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. *Pharmacogenetics and Genomics*, **2002**, 12, 635-45		71
98	The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. *British Journal of Clinical Pharmacology*, **2001**, 52, 605-9	3.8	88
97	Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. *Pharmacogenetics and Genomics*, **2000**, 10, 679-85		214
96	Nonspecific binding of drugs to human liver microsomes. *British Journal of Clinical Pharmacology*, **2000**, 49, 453-61	3.8	116
95	The xenobiotic inhibitor profile of cytochrome P4502C8. *British Journal of Clinical Pharmacology*, **2000**, 50, 573-80	3.8	66
94	Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. *Clinical Chemistry and Laboratory Medicine*, **2000**, 38, 889-92	5.9	81
93	Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. *Pharmacogenetics and Genomics*, **2000**, 10, 267-70		48
92	Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. *British Journal of Clinical Pharmacology*, **1999**, 47, 299-305	3.8	27
91	Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. *British Journal of Clinical Pharmacology*, **1998**, 45, 525-38	3.8	678
90	Baculovirus-mediated expression of cytochrome P4502C8 and human NADPH-cytochrome P450 reductase: optimization of protein expression. *Xenobiotica*, **1998**, 28, 137-52	2	6
89	Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. *Xenobiotica*, **1998**, 28, 293-301	2	25
88	The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. *Archives of Biochemistry and Biophysics*, **1997**, 341, 207-11	4.1	63
87	Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. *British Journal of Clinical Pharmacology*, **1997**, 43, 245-52	3.8	69
86	1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect. *British Journal of Clinical Pharmacology*, **1997**, 43, 197-200	3.8	7
85	Allelic and functional variability of cytochrome P4502C9. *Pharmacogenetics and Genomics*, **1997**, 7, 51-8		82
84	Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. *Methods in Enzymology*, **1996**, 272, 139-45	1.7	59

83	Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. *Biochemical Pharmacology*, **1996**, 51, 1003-8	6	101
82	The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. *Pharmacogenetics and Genomics*, **1996**, 6, 341-9		549
81	Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. *Methods in Enzymology*, **1996**, 272, 132-9	1.7	12
80	The use of caffeine as a metabolic probe for human drug metabolizing enzymes. *General Pharmacology*, **1996**, 27, 245-9		82
79	Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. *British Journal of Clinical Pharmacology*, **1996**, 42, 774-8	3.8	10
78	Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. *British Journal of Clinical Pharmacology*, **1996**, 41, 299-304	3.8	48
77	Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans. *British Journal of Clinical Pharmacology*, **1995**, 40, 153-6	3.8	16
76	Dispositional factors do not contribute to the enantiospecificity of the cardiovascular effects of phenylpropanolamine. *Clinical Pharmacology and Therapeutics*, **1994**, 55, 35-43	6.1	4
75	Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. *Biochemical Pharmacology*, **1994**, 47, 1767-76	6	151
74	Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. *British Journal of Clinical Pharmacology*, **1994**, 37, 597-604	3.8	104
73	Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. *British Journal of Clinical Pharmacology*, **1994**, 38, 131-7	3.8	168
72	In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. *British Journal of Clinical Pharmacology*, **1994**, 37, 413-20	3.8	57
71	New uses for allopurinol. *Drugs*, **1994**, 48, 339-44	12.1	13
70	Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism. *Annual Reports in Medicinal Chemistry*, **1994**, 29, 307-316	1.6	27
69	Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. *Pharmacogenetics and Genomics*, **1994**, 4, 281-4		30
68	cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. *Biochemical and Biophysical Research Communications*, **1993**, 194, 496-503	3.4	100
67	Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. *British Journal of Clinical Pharmacology*, **1993**, 36, 521-30	3.8	161
66	In vitro approaches can predict human drug metabolism. *Trends in Pharmacological Sciences*, **1993**, 14, 292-4	13.2	59

65	The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. *Carcinogenesis*, **1993**, 14, 2637-9	4.6	62
64	Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. *Pharmacogenetics and Genomics*, **1993**, 3, 86-93		40
63	High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. *Biomedical Applications*, **1993**, 616, 73-8		52
62	High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism. *Biomedical Applications*, **1993**, 619, 291-7		17
61	Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. *Biochemical Pharmacology*, **1993**, 46, 1975-81	6	114
60	Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. *Pharmacogenetics and Genomics* , **1992**, 2, 173-83		86
59	Perturbation of paracetamol urinary metabolic ratios by urine flow rate. *British Journal of Clinical Pharmacology*, **1992**, 34, 359-62	3.8	9
58	Stereospecific high-performance liquid chromatographic assay for the enantiomers of phenylpropanolamine in human plasma. *Therapeutic Drug Monitoring*, **1991**, 13, 332-8	3.2	5
57	Drug glucuronidation in humans **1991**, 51, 347-69		282
56	1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect. *British Journal of Clinical Pharmacology*, **1991**, 32, 238-41	3.8	7
55	Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. *British Journal of Clinical Pharmacology*, **1991**, 31, 125-30	3.8	85
54	Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. *British Journal of Clinical Pharmacology*, **1991**, 31, 405-8	3.8	49
53	Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. *Biochemical and Biophysical Research Communications*, **1991**, 175, 1112-8	3.4	182
52	Assessment of the drug inhibitor specificity of the human liver 4-methylumbelliferone UDP-glucuronosyltransferase activity. *Biochemical Pharmacology*, **1991**, 41, 838-41	6	9
51	Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. *Clinical Pharmacology and Therapeutics*, **1990**, 47, 403-11	6.1	99
50	Mechanism of formation of 6-amino-5-(N-methylformylamino)-1-methyluracil and 3,7-dimethyluric acid from theobromine in the rat in vitro: involvement of cytochrome P-450 and a cellular thiol. *Xenobiotica*, **1990**, 20, 823-33	2	7
49	Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. *Biochemical Pharmacology*, **1990**, 40, 595-600	6	38
48	Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. *Clinical Pharmacokinetics*, **1989**, 17, 327-44	6.2	50

47	Biochemical validation of self-reported caffeine consumption during caffeine fading. *Journal of Behavioral Medicine*, **1988**, 11, 15-30	3.6	35
46	Comparison of paracetamol metabolism in young adult and elderly males. *European Journal of Clinical Pharmacology*, **1988**, 35, 157-60	2.8	65
45	Direct and simultaneous high-performance liquid chromatographic assay for the determination of p-aminobenzoic acid and its conjugates in human urine. *Biomedical Applications*, **1988**, 426, 103-9		23
44	Radiometric high-performance liquid chromatographic procedure for the determination of theobromine metabolites in microsomal incubations. *Biomedical Applications*, **1988**, 430, 203-6		2
43	In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. *Biochemical Pharmacology*, **1988**, 37, 2839-45	6	48
42	Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. *Biochemical Pharmacology*, **1988**, 37, 665-71	6	51
41	Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. *Biochemical Pharmacology*, **1988**, 37, 1651-9	6	103
40	Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. *Biochemical Pharmacology*, **1988**, 37, 1137-44	6	163
39	Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline. *British Journal of Clinical Pharmacology*, **1988**, 25, 397-400	3.8	19
38	Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. *British Journal of Clinical Pharmacology*, **1988**, 26, 423-8	3.8	39
37	Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. *British Journal of Clinical Pharmacology*, **1988**, 26, 429-34	3.8	31
36	Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition. *British Journal of Clinical Pharmacology*, **1987**, 23, 772-5	3.8	8
35	Characterisation of theophylline metabolism in human liver microsomes. *British Journal of Clinical Pharmacology*, **1987**, 24, 293-300	3.8	90
34	Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. *Clinical Pharmacology and Therapeutics*, **1986**, 39, 54-9	6.1	140
33	Paracetamol metabolism in pregnancy. *British Journal of Clinical Pharmacology*, **1986**, 22, 359-62	3.8	57
32	Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. *British Journal of Clinical Pharmacology*, **1986**, 22, 135-42	3.8	63
31	Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. *British Journal of Clinical Pharmacology*, **1986**, 22, 177-82	3.8	110
30	Quantitative assessment of caffeine partial clearances in man. *British Journal of Clinical Pharmacology*, **1986**, 22, 183-6	3.8	97

29	The Analysis of Penicillins in Biological Fluids and Pharmaceutical Preparations by High-Performance Liquid Chromatography: A Review. *Journal of Liquid Chromatography and Related Technologies*, **1985**, 8, 2827-2843		16
28	Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. *Australian and New Zealand Journal of Medicine*, **1985**, 15, 348-9		28
27	Verapamil disposition--effects of sulphinpyrazone and cimetidine. *British Journal of Clinical Pharmacology*, **1985**, 19, 385-91	3.8	26
26	The effect of ranitidine on the disposition of lignocaine. *British Journal of Clinical Pharmacology*, **1985**, 20, 170-3	3.8	15
25	Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. *British Journal of Clinical Pharmacology*, **1985**, 20, 219-23	3.8	27
24	Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. *British Journal of Clinical Pharmacology*, **1985**, 20, 482-5	3.8	30
23	Liquid gastric emptying assessed by direct and indirect techniques: radionuclide labelled liquid emptying compared with a simple paracetamol marker method. *ANZ Journal of Surgery*, **1985**, 55, 203-6	1	30
22	A simple HPLC assay for urinary paracetamol metabolites and its use to characterize the C3H mouse as a model for paracetamol metabolism studies. *Clinical and Experimental Pharmacology and Physiology*, **1984**, 11, 209-17	3	26
21	Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. *Clinical Pharmacology and Therapeutics*, **1984**, 35, 480-6	6.1	79
20	Lidocaine disposition--sex differences and effects of cimetidine. *Clinical Pharmacology and Therapeutics*, **1984**, 35, 695-701	6.1	57
19	Clinical pharmacology of GP53,633--a new non-steroidal anti-inflammatory drug--in patients with rheumatoid arthritis. *Agents and Actions*, **1984**, 15, 424-7		
18	Differential effects of cimetidine on theophylline metabolic pathways. *European Journal of Clinical Pharmacology*, **1984**, 26, 335-40	2.8	71
17	Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. *British Journal of Clinical Pharmacology*, **1984**, 18, 240-3	3.8	48
16	Theophylline-rifampicin interaction: non-selective induction of theophylline metabolic pathways. *British Journal of Clinical Pharmacology*, **1984**, 18, 445-8	3.8	27
15	Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. *British Journal of Clinical Pharmacology*, **1984**, 18, 853-60	3.8	25
14	Effect of cimetidine on paracetamol activation in mice. *Biochemical Pharmacology*, **1984**, 33, 1996-8	6	9
13	The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. *Biochemical Pharmacology*, **1984**, 33, 2989-94	6	194
12	Mechanism of action of paracetamol protective agents in mice in vivo. *Biochemical Pharmacology*, **1984**, 33, 2995-3000	6	108

11	Nonlinear metabolic disposition of theophylline. *Therapeutic Drug Monitoring*, **1984**, 6, 290-7	3.2	27
10	Analysis of D-penicillamine in plasma by fluorescence derivatisation with N-[p-(2-benzoxazolyl)-phenyl] maleimide and high-performance liquid chromatography. *Biomedical Applications*, **1983**, 275, 89-96		31
9	Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid. *British Journal of Clinical Pharmacology*, **1983**, 15, 117-9	3.8	45
8	Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. *British Journal of Clinical Pharmacology*, **1983**, 15, 567-9	3.8	23
7	Influence of sex and oral contraceptive steroids on paracetamol metabolism. *British Journal of Clinical Pharmacology*, **1983**, 16, 503-9	3.8	151
6	Ranitidine disposition in patients with renal impairment. *British Journal of Clinical Pharmacology*, **1983**, 16, 731-4	3.8	17
5	The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. *European Journal of Clinical Pharmacology*, **1982**, 22, 321-6	2.8	39
4	Interaction of sulphinpyrazone with warfarin. *European Journal of Clinical Pharmacology*, **1982**, 22, 327-31	2.8	17
3	The simultaneous determination of theophylline, theobromine and caffeine in plasma by high performance liquid chromatography. *Clinical Biochemistry*, **1980**, 13, 132-4	3.5	31
2	Cimetidine interaction with warfarin. *Lancet, The*, **1979**, 2, 639	40	34
1	Additivity relationships in carbon-13 nuclear magnetic resonance spectra of dihydroxy steroids. *Journal of Organic Chemistry*, **1977**, 42, 789-93	4.2	81